Baidu
map

AP&T: 挥发性麻醉药七氟醚和地氟醚对药物性肝损伤发生率的前瞻性研究

2019-04-15 不详 MedSci原创

已知挥发性麻醉剂会引起药物诱导的肝损伤,肝毒性反应的特征在于对三氟乙酰化脂质和蛋白质和细胞色素p450 2E1的抗体的产生。目前学界对于较老药物引起的挥发性麻醉药物引起的肝损伤的已有明确的认识,但是现代药物如七氟醚和地氟醚尚未进行前瞻性研究。因此,本项研究旨在进行前瞻性地研究以确定七氟醚和地氟醚对挥发性麻醉药物引起的肝损伤的发生率。

背景
已知挥发性麻醉剂会引起药物诱导的肝损伤,肝毒性反应的特征在于对三氟乙酰化脂质和蛋白质和细胞色素p450 2E1的抗体的产生。目前学界对于较老药物引起的挥发性麻醉药物引起的肝损伤的已有明确的认识,但是现代药物如七氟醚和地氟醚尚未进行前瞻性研究。因此,本项研究旨在进行前瞻性地研究以确定七氟醚和地氟醚对挥发性麻醉药物引起的肝损伤的发生率。

方法
研究人员招募了接受手术且至少住院4天的的成人外科患者。如果给予挥发性麻醉剂,则定期进行肝脏生物标志物检测。同时记录了药物使用情况,肝脏生化异常的患者根据临床评估,以及其他可能的病理学表现来判断是否造成药物诱导的肝损伤。还测试了一些患者对三氟乙酰化脂质和蛋白质以及细胞色素p450 2E1的抗体情况。

结果
本项研究共招募了209名患者,其中121名被纳入分析。62例患者术后肝脏生化异常(51.2%); 进一步分类为非挥发性麻醉药物致肝损伤47例(38.8%),可能挥发性麻醉药物致肝损伤15例(12.4%)。因此,临床上显着的挥发性麻醉药物诱导的肝损伤的发生率为4.1%。

结论
现代麻醉药物七氟醚和地氟醚药物引起的肝损伤似乎与之前报道的老年药物(3%)一样普遍(4.1%)。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1826521, encodeId=53a4182652147, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat May 25 21:01:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006456, encodeId=c5b92006456db, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Fri Apr 26 15:01:00 CST 2019, time=2019-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914466, encodeId=72781914466b4, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Jun 10 17:01:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992127, encodeId=3995199212ef0, content=<a href='/topic/show?id=d4cb413e6e2' target=_blank style='color:#2F92EE;'>#地氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41376, encryptionId=d4cb413e6e2, topicName=地氟醚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Thu Feb 27 21:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655568, encodeId=71de165556822, content=<a href='/topic/show?id=f65356495ca' target=_blank style='color:#2F92EE;'>#挥发性麻醉药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56495, encryptionId=f65356495ca, topicName=挥发性麻醉药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19fe24733055, createdName=apoenzyme, createdTime=Sun Jan 26 06:01:00 CST 2020, time=2020-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338800, encodeId=ea7a13388007d, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397745, encodeId=52e1139e74578, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412695, encodeId=25421412695fa, content=<a href='/topic/show?id=1c2f195092d' target=_blank style='color:#2F92EE;'>#七氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19509, encryptionId=1c2f195092d, topicName=七氟醚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a102881238, createdName=linagood, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540077, encodeId=e39215400e7b6, content=<a href='/topic/show?id=52f28e736c9' target=_blank style='color:#2F92EE;'>#药物性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87736, encryptionId=52f28e736c9, topicName=药物性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55e413178317, createdName=yangfl10, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1826521, encodeId=53a4182652147, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat May 25 21:01:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006456, encodeId=c5b92006456db, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Fri Apr 26 15:01:00 CST 2019, time=2019-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914466, encodeId=72781914466b4, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Jun 10 17:01:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992127, encodeId=3995199212ef0, content=<a href='/topic/show?id=d4cb413e6e2' target=_blank style='color:#2F92EE;'>#地氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41376, encryptionId=d4cb413e6e2, topicName=地氟醚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Thu Feb 27 21:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655568, encodeId=71de165556822, content=<a href='/topic/show?id=f65356495ca' target=_blank style='color:#2F92EE;'>#挥发性麻醉药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56495, encryptionId=f65356495ca, topicName=挥发性麻醉药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19fe24733055, createdName=apoenzyme, createdTime=Sun Jan 26 06:01:00 CST 2020, time=2020-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338800, encodeId=ea7a13388007d, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397745, encodeId=52e1139e74578, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412695, encodeId=25421412695fa, content=<a href='/topic/show?id=1c2f195092d' target=_blank style='color:#2F92EE;'>#七氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19509, encryptionId=1c2f195092d, topicName=七氟醚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a102881238, createdName=linagood, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540077, encodeId=e39215400e7b6, content=<a href='/topic/show?id=52f28e736c9' target=_blank style='color:#2F92EE;'>#药物性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87736, encryptionId=52f28e736c9, topicName=药物性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55e413178317, createdName=yangfl10, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1826521, encodeId=53a4182652147, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat May 25 21:01:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006456, encodeId=c5b92006456db, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Fri Apr 26 15:01:00 CST 2019, time=2019-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914466, encodeId=72781914466b4, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Jun 10 17:01:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992127, encodeId=3995199212ef0, content=<a href='/topic/show?id=d4cb413e6e2' target=_blank style='color:#2F92EE;'>#地氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41376, encryptionId=d4cb413e6e2, topicName=地氟醚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Thu Feb 27 21:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655568, encodeId=71de165556822, content=<a href='/topic/show?id=f65356495ca' target=_blank style='color:#2F92EE;'>#挥发性麻醉药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56495, encryptionId=f65356495ca, topicName=挥发性麻醉药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19fe24733055, createdName=apoenzyme, createdTime=Sun Jan 26 06:01:00 CST 2020, time=2020-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338800, encodeId=ea7a13388007d, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397745, encodeId=52e1139e74578, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412695, encodeId=25421412695fa, content=<a href='/topic/show?id=1c2f195092d' target=_blank style='color:#2F92EE;'>#七氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19509, encryptionId=1c2f195092d, topicName=七氟醚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a102881238, createdName=linagood, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540077, encodeId=e39215400e7b6, content=<a href='/topic/show?id=52f28e736c9' target=_blank style='color:#2F92EE;'>#药物性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87736, encryptionId=52f28e736c9, topicName=药物性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55e413178317, createdName=yangfl10, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1826521, encodeId=53a4182652147, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat May 25 21:01:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006456, encodeId=c5b92006456db, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Fri Apr 26 15:01:00 CST 2019, time=2019-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914466, encodeId=72781914466b4, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Jun 10 17:01:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992127, encodeId=3995199212ef0, content=<a href='/topic/show?id=d4cb413e6e2' target=_blank style='color:#2F92EE;'>#地氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41376, encryptionId=d4cb413e6e2, topicName=地氟醚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Thu Feb 27 21:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655568, encodeId=71de165556822, content=<a href='/topic/show?id=f65356495ca' target=_blank style='color:#2F92EE;'>#挥发性麻醉药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56495, encryptionId=f65356495ca, topicName=挥发性麻醉药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19fe24733055, createdName=apoenzyme, createdTime=Sun Jan 26 06:01:00 CST 2020, time=2020-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338800, encodeId=ea7a13388007d, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397745, encodeId=52e1139e74578, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412695, encodeId=25421412695fa, content=<a href='/topic/show?id=1c2f195092d' target=_blank style='color:#2F92EE;'>#七氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19509, encryptionId=1c2f195092d, topicName=七氟醚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a102881238, createdName=linagood, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540077, encodeId=e39215400e7b6, content=<a href='/topic/show?id=52f28e736c9' target=_blank style='color:#2F92EE;'>#药物性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87736, encryptionId=52f28e736c9, topicName=药物性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55e413178317, createdName=yangfl10, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
    2020-02-27 lsj628
  5. [GetPortalCommentsPageByObjectIdResponse(id=1826521, encodeId=53a4182652147, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat May 25 21:01:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006456, encodeId=c5b92006456db, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Fri Apr 26 15:01:00 CST 2019, time=2019-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914466, encodeId=72781914466b4, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Jun 10 17:01:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992127, encodeId=3995199212ef0, content=<a href='/topic/show?id=d4cb413e6e2' target=_blank style='color:#2F92EE;'>#地氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41376, encryptionId=d4cb413e6e2, topicName=地氟醚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Thu Feb 27 21:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655568, encodeId=71de165556822, content=<a href='/topic/show?id=f65356495ca' target=_blank style='color:#2F92EE;'>#挥发性麻醉药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56495, encryptionId=f65356495ca, topicName=挥发性麻醉药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19fe24733055, createdName=apoenzyme, createdTime=Sun Jan 26 06:01:00 CST 2020, time=2020-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338800, encodeId=ea7a13388007d, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397745, encodeId=52e1139e74578, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412695, encodeId=25421412695fa, content=<a href='/topic/show?id=1c2f195092d' target=_blank style='color:#2F92EE;'>#七氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19509, encryptionId=1c2f195092d, topicName=七氟醚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a102881238, createdName=linagood, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540077, encodeId=e39215400e7b6, content=<a href='/topic/show?id=52f28e736c9' target=_blank style='color:#2F92EE;'>#药物性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87736, encryptionId=52f28e736c9, topicName=药物性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55e413178317, createdName=yangfl10, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1826521, encodeId=53a4182652147, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat May 25 21:01:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006456, encodeId=c5b92006456db, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Fri Apr 26 15:01:00 CST 2019, time=2019-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914466, encodeId=72781914466b4, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Jun 10 17:01:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992127, encodeId=3995199212ef0, content=<a href='/topic/show?id=d4cb413e6e2' target=_blank style='color:#2F92EE;'>#地氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41376, encryptionId=d4cb413e6e2, topicName=地氟醚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Thu Feb 27 21:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655568, encodeId=71de165556822, content=<a href='/topic/show?id=f65356495ca' target=_blank style='color:#2F92EE;'>#挥发性麻醉药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56495, encryptionId=f65356495ca, topicName=挥发性麻醉药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19fe24733055, createdName=apoenzyme, createdTime=Sun Jan 26 06:01:00 CST 2020, time=2020-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338800, encodeId=ea7a13388007d, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397745, encodeId=52e1139e74578, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412695, encodeId=25421412695fa, content=<a href='/topic/show?id=1c2f195092d' target=_blank style='color:#2F92EE;'>#七氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19509, encryptionId=1c2f195092d, topicName=七氟醚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a102881238, createdName=linagood, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540077, encodeId=e39215400e7b6, content=<a href='/topic/show?id=52f28e736c9' target=_blank style='color:#2F92EE;'>#药物性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87736, encryptionId=52f28e736c9, topicName=药物性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55e413178317, createdName=yangfl10, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1826521, encodeId=53a4182652147, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat May 25 21:01:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006456, encodeId=c5b92006456db, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Fri Apr 26 15:01:00 CST 2019, time=2019-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914466, encodeId=72781914466b4, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Jun 10 17:01:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992127, encodeId=3995199212ef0, content=<a href='/topic/show?id=d4cb413e6e2' target=_blank style='color:#2F92EE;'>#地氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41376, encryptionId=d4cb413e6e2, topicName=地氟醚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Thu Feb 27 21:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655568, encodeId=71de165556822, content=<a href='/topic/show?id=f65356495ca' target=_blank style='color:#2F92EE;'>#挥发性麻醉药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56495, encryptionId=f65356495ca, topicName=挥发性麻醉药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19fe24733055, createdName=apoenzyme, createdTime=Sun Jan 26 06:01:00 CST 2020, time=2020-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338800, encodeId=ea7a13388007d, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397745, encodeId=52e1139e74578, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412695, encodeId=25421412695fa, content=<a href='/topic/show?id=1c2f195092d' target=_blank style='color:#2F92EE;'>#七氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19509, encryptionId=1c2f195092d, topicName=七氟醚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a102881238, createdName=linagood, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540077, encodeId=e39215400e7b6, content=<a href='/topic/show?id=52f28e736c9' target=_blank style='color:#2F92EE;'>#药物性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87736, encryptionId=52f28e736c9, topicName=药物性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55e413178317, createdName=yangfl10, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1826521, encodeId=53a4182652147, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat May 25 21:01:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006456, encodeId=c5b92006456db, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Fri Apr 26 15:01:00 CST 2019, time=2019-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914466, encodeId=72781914466b4, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Jun 10 17:01:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992127, encodeId=3995199212ef0, content=<a href='/topic/show?id=d4cb413e6e2' target=_blank style='color:#2F92EE;'>#地氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41376, encryptionId=d4cb413e6e2, topicName=地氟醚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Thu Feb 27 21:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655568, encodeId=71de165556822, content=<a href='/topic/show?id=f65356495ca' target=_blank style='color:#2F92EE;'>#挥发性麻醉药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56495, encryptionId=f65356495ca, topicName=挥发性麻醉药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19fe24733055, createdName=apoenzyme, createdTime=Sun Jan 26 06:01:00 CST 2020, time=2020-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338800, encodeId=ea7a13388007d, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397745, encodeId=52e1139e74578, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412695, encodeId=25421412695fa, content=<a href='/topic/show?id=1c2f195092d' target=_blank style='color:#2F92EE;'>#七氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19509, encryptionId=1c2f195092d, topicName=七氟醚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a102881238, createdName=linagood, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540077, encodeId=e39215400e7b6, content=<a href='/topic/show?id=52f28e736c9' target=_blank style='color:#2F92EE;'>#药物性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87736, encryptionId=52f28e736c9, topicName=药物性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55e413178317, createdName=yangfl10, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1826521, encodeId=53a4182652147, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat May 25 21:01:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006456, encodeId=c5b92006456db, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Fri Apr 26 15:01:00 CST 2019, time=2019-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914466, encodeId=72781914466b4, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Jun 10 17:01:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992127, encodeId=3995199212ef0, content=<a href='/topic/show?id=d4cb413e6e2' target=_blank style='color:#2F92EE;'>#地氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41376, encryptionId=d4cb413e6e2, topicName=地氟醚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Thu Feb 27 21:01:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655568, encodeId=71de165556822, content=<a href='/topic/show?id=f65356495ca' target=_blank style='color:#2F92EE;'>#挥发性麻醉药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56495, encryptionId=f65356495ca, topicName=挥发性麻醉药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19fe24733055, createdName=apoenzyme, createdTime=Sun Jan 26 06:01:00 CST 2020, time=2020-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338800, encodeId=ea7a13388007d, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397745, encodeId=52e1139e74578, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412695, encodeId=25421412695fa, content=<a href='/topic/show?id=1c2f195092d' target=_blank style='color:#2F92EE;'>#七氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19509, encryptionId=1c2f195092d, topicName=七氟醚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a102881238, createdName=linagood, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540077, encodeId=e39215400e7b6, content=<a href='/topic/show?id=52f28e736c9' target=_blank style='color:#2F92EE;'>#药物性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87736, encryptionId=52f28e736c9, topicName=药物性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55e413178317, createdName=yangfl10, createdTime=Wed Apr 17 07:01:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]

相关资讯

GUT:食管胃底静脉曲张出血后早期使用止血粉的疗效分析

急性静脉曲张出血(AVB)需要经验丰富的内镜医师进行早期治疗,这往往会导致临床工作中效率低下。因此,本项研究旨在评估了一种不同的管理理念即将早期应用止血粉加入食管胃底静脉曲张出血常规治疗方案。

一图看懂RCT的套路

大家都知道循证医学中证据等级最高的一类研究就是Randomized clinical trials(RCT)。在NEJM,Lancet,JAMA,BMJ等高影响因子的期刊上,每期都会有有RCT论文的身影(甚至每期好几篇RCT),真可谓“paper霸”。RCT论文雄霸这些大刊的原因很简单,就是因为这些研究可以“一锤定音”,一般认为RCT是确证性研究,通过它可以验证规律,可以得到明确、高论证强度的结论

Clin Gastroenterology H: 布地奈德栓剂治疗急性溃疡性直肠炎是有效和安全的

虽然直肠炎是溃疡性结肠炎中最轻的病症,但它会引起一系列症状。美沙拉嗪的标准治疗方案并不总是有效。因此,研究人员进行了一项随机对照试验,以确定布地奈德栓剂与美沙拉嗪栓剂联合布地奈德治疗直肠炎的疗效和安全性。

J Endod:根管治疗对牙本质抗折断的影响

尽管随着年龄的增长牙本质强度和韧性降低,但还没有研究显示修复治疗是否对其是一种促进因素。

AP&T: DPP-4抑制剂维达列汀可抑制胃调节并增加胰高血糖素样肽-1血浆水平

有文献报道二肽基肽酶-4(DPP-4)可以使胰高血糖素样肽-1(GLP-1)失活。但DPP-4抑制剂是否影响人的GLP-1代谢和/或食物摄入仍然未知。因此,本项研究旨在评估维格列汀(DPP-4抑制剂)对健康志愿者(HVs)胃适应和随意摄取食物的影响。

GUT: 高危消化道溃疡出血内镜下止血后加用血管栓塞效果分析

在治疗消化性溃疡出血患者中,复发性出血与高死亡率相关。因此,本项研究旨在探究内镜下止血后增加血管造影栓塞是否可以减少复发性出血的概率。

Baidu
map
Baidu
map
Baidu
map